Form 4: Director Napoleone Ferrara Receives Kalaris Stock Options

Director Napoleone Ferrara was granted 9,000 stock options in Kalaris Therapeutics, Inc. on June 3, 2026.

Summary

• Director Napoleone Ferrara acquired 9,000 stock options in Kalaris Therapeutics, Inc. (KLRS).
• The options have an exercise price of $4.72 per share.
• The grant date for these options is June 3, 2026.
• The options are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard compensation packages for small-cap biotech firms.
• The one-year cliff vesting schedule is a common retention mechanism for board members in the industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 3, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Form 4, Insider Trading, Stock Options, Director Compensation